• Leukemias, lymphomas, and other hematologic cancers

Depocyt Generic Name & Formulations

General Description

Cytarabine 50mg/vial; liposomal suspension for intrathecal administration; preservative-free.

Pharmacological Class


How Supplied

Single-use vials (5mL)—1

Depocyt Indications


Intrathecal treatment of lymphomatous meningitis.

Depocyt Dosage and Administration


See full labeling. Give intrathecally over 1–5 minutes. Administer dexamethasone 4mg twice daily for 5 days with each cycle of treatment. Induction: 50mg every 14 days for 2 doses (weeks 1 and 3). Consolidation: 50mg every 14 days for 3 doses (weeks 5, 7 and 9) followed by 1 additional dose at week 13. Maintenance: 50mg every 28 days for 4 doses (weeks 17, 21, 25 and 29). Reduce dose to 25mg if neurotoxicity develops and discontinue if it persists.


Not recommended.

Depocyt Contraindications


Active meningeal infection.

Depocyt Boxed Warnings

Not Applicable

Depocyt Warnings/Precautions


Chemical arachnoiditis; reduce symptoms with dexamethasone. Previous irradiation, cytotoxic chemotherapy. Monitor blood counts and for development of neurotoxicity. Renal and hepatic impairment. Pregnancy (Cat.D); avoid use. Nursing mothers: not recommended.

Depocyt Pharmacokinetics

See Literature

Depocyt Interactions


Increased risk of neurotoxicity with concomitant cranial/spinal irradiation or other intrathecal antineoplastics.

Depocyt Adverse Reactions

Adverse Reactions

See full labeling. Arachnoiditis, GI upset, headache, fever, neurological toxicity (myelopathy), hydrocephalus, elevated CSF protein and WBC, weakness, back pain, insomnia, blurred vision, anaphylactic reactions; others.

Depocyt Clinical Trials

See Literature

Depocyt Note

Not Applicable

Depocyt Patient Counseling

See Literature